Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Surgical patches recalled | 3-in-1 TAVR guidewire impresses | Stem cell company acquires cardiology practices | SCAI & CRT unite
Thursday, December 4, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA announces Class I recall of patches used for heart surgery

There is a risk of certain pericardial patches not being as strong or durable as needed. Customers are urged to identify, quarantine and replace these devices.

READ MORE >
FDA recall medical device recall product recall
Share on Twitter Share on Facebook Share on Linkedin

FDA announces Class I recall of patches used for heart surgery

Share on Twitter Share on Facebook Share on Linkedin
FDA recall medical device recall product recall
There is a risk of certain pericardial patches not being as strong or durable as needed. Customers are urged to identify, quarantine and replace these devices.
READ MORE >

3-in-1 TAVR guidewire linked to faster procedures, less radiation

The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition. 

READ MORE >
SavvyWire OpSens TAVR guidewire owned by Haemonetics. the SavvyWire guidewire, a sensor-guided device developed by OpSens Medical, a Canadian medical device company. According to OpSens, the SavvyWire is the first interventional device of its kind. It provides assistance with aortic valve delivery and positioning, like any guidewire, but it also includes sensors that enable continuous hemodynamic measurements and rapid LV pacing.
Share on Twitter Share on Facebook Share on Linkedin

3-in-1 TAVR guidewire linked to faster procedures, less radiation

Share on Twitter Share on Facebook Share on Linkedin
SavvyWire OpSens TAVR guidewire owned by Haemonetics. the SavvyWire guidewire, a sensor-guided device developed by OpSens Medical, a Canadian medical device company. According to OpSens, the SavvyWire is the first interventional device of its kind. It provides assistance with aortic valve delivery and positioning, like any guidewire, but it also includes sensors that enable continuous hemodynamic measurements and rapid LV pacing.
The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition. 
READ MORE >

Stem cell company acquires 2 cardiology practices, calling them ‘the first of many’

Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform. 

READ MORE >
merger acquisition M&A business
Share on Twitter Share on Facebook Share on Linkedin

Stem cell company acquires 2 cardiology practices, calling them ‘the first of many’

Share on Twitter Share on Facebook Share on Linkedin
merger acquisition M&A business
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform. 
READ MORE >

Interventional cardiology groups unite to push the specialty forward

SCAI and CRT have announced a new partnership focused on education, advocacy and research.

READ MORE >
Heart doctors and surgeons working together. Top cardiology hospitals in the United States.
Share on Twitter Share on Facebook Share on Linkedin

Interventional cardiology groups unite to push the specialty forward

Share on Twitter Share on Facebook Share on Linkedin
Heart doctors and surgeons working together. Top cardiology hospitals in the United States.
SCAI and CRT have announced a new partnership focused on education, advocacy and research.
READ MORE >

Featured Articles

Doctors still unsure about Trump’s heart health after ‘weird’ memo

It is still unclear which imaging exams President Donald Trump underwent to evaluate his cardiovascular health. The White House shared a memo Monday as an attempt to put this topic to bed—but questions remain. 

READ MORE >
President Donald Trump, White House press photo.
Share on Twitter Share on Facebook Share on Linkedin

Doctors still unsure about Trump’s heart health after ‘weird’ memo

Share on Twitter Share on Facebook Share on Linkedin
President Donald Trump, White House press photo.
It is still unclear which imaging exams President Donald Trump underwent to evaluate his cardiovascular health. The White House shared a memo Monday as an attempt to put this topic to bed—but questions remain. 
READ MORE >

AI has already transformed TAVR care—and the best is yet to come

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 

READ MORE >
Cardiologist Heart Doctor Tablet Technology
Share on Twitter Share on Facebook Share on Linkedin

AI has already transformed TAVR care—and the best is yet to come

Share on Twitter Share on Facebook Share on Linkedin
Cardiologist Heart Doctor Tablet Technology
Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 
READ MORE >

Siemens Healthineers unveils new AI-powered CCTA software

The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. 

READ MORE >
Siemens Healthineers software Syngo.CT Coronary Cockpit
Share on Twitter Share on Facebook Share on Linkedin

Siemens Healthineers unveils new AI-powered CCTA software

Share on Twitter Share on Facebook Share on Linkedin
Siemens Healthineers software Syngo.CT Coronary Cockpit
The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. 
READ MORE >

In Case You Missed It

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes. 

READ MORE >
Cleerly AI plaque and coronary artery analysis at SCCT 2023. Photo by Dave Fornell
Share on Twitter Share on Facebook Share on Linkedin

AI-enabled coronary plaque quantification outperforms traditional risk scores

Share on Twitter Share on Facebook Share on Linkedin
Cleerly AI plaque and coronary artery analysis at SCCT 2023. Photo by Dave Fornell
Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes. 
READ MORE >

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

READ MORE >
Heart in coffee at TCT 2023. Photo by Dave Fornell
Share on Twitter Share on Facebook Share on Linkedin

Drinking coffee may reduce risk of recurrent AFib

Share on Twitter Share on Facebook Share on Linkedin
Heart in coffee at TCT 2023. Photo by Dave Fornell
Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.
READ MORE >

$64M raised for new cardiogenic shock drug—research already underway

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.

READ MORE >
Illustration showing how procizumab captures circulating dipeptidyl peptidase 3 (cDPP3) to block this key molecular driver of shock. Illustrations courtesy of 4TEEN4
Share on Twitter Share on Facebook Share on Linkedin

$64M raised for new cardiogenic shock drug—research already underway

Share on Twitter Share on Facebook Share on Linkedin
Illustration showing how procizumab captures circulating dipeptidyl peptidase 3 (cDPP3) to block this key molecular driver of shock. Illustrations courtesy of 4TEEN4
Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.
READ MORE >

In Other News

Data show ‘alarming’ rise in invasive breast cancer cases among younger women

Between 20% to 24% of all breast cancers diagnosed during a decade-long period were found in women between the ages of 18 to 49, according to research presented at RSNA 2025. 

READ MORE >
mammogram mammography breast cancer
Share on Twitter Share on Facebook Share on Linkedin

Data show ‘alarming’ rise in invasive breast cancer cases among younger women

Share on Twitter Share on Facebook Share on Linkedin
mammogram mammography breast cancer
Between 20% to 24% of all breast cancers diagnosed during a decade-long period were found in women between the ages of 18 to 49, according to research presented at RSNA 2025. 
READ MORE >

CVS agrees to pay $38M to resolve insulin over-distribution allegations, DOJ says

Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade. 

READ MORE >
CVS Health announces $10.6B acquisition of Oak Street Health
Share on Twitter Share on Facebook Share on Linkedin

CVS agrees to pay $38M to resolve insulin over-distribution allegations, DOJ says

Share on Twitter Share on Facebook Share on Linkedin
CVS Health announces $10.6B acquisition of Oak Street Health
Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup